

Conference Call/Webcast

Thursday, November 4, 2021

9:00am ET

▲ ALBEMARLE®

Forward-Looking Statements –

Some of the information presented in this presentation, the conference call and discussions that follow, including, without limitation, statements with respect to product development, market trends, price, expected growth and earnings, demand for our products, capital projects, tax rates, stock repurchases, dividends, cash flow generation, economic trends, outlook, guidance, and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed.

Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentation. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.



Non-GAAP Financial Measures

It should be noted that adjusted net income attributable to Albemarle Corporation ("adjusted earnings"), adjusted diluted earnings per share attributable to Albemarle Corporation, adjusted effective income tax rates, segment operating profit, segment income, pro-forma net sales, net sales excluding the impact of foreign exchange translation ("ex FX"), EBITDA, adjusted EBITDA, adjusted EBITDA by operating segment, EBITDA margin, adjusted EBITDA margin, pro-forma adjusted EBITDA, pro-forma adjusted EBITDA margin, adjusted EBITDA ex FX, adjusted EBITDA margin ex FX, net debt to adjusted EBITDA, and gross debt to adjusted EBITDA are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance. The Company's chief operating decision makers use these measures to assess the ongoing performance of the Company and its segments, as well as for business and enterprise planning purposes.

A description of these and other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Appendix to this presentation. The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the Company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the Company's results calculated in accordance with GAAP.



Recent Accomplishments Support Long-term Growth

Q3 2021 net sales \$831M, up 11% Y/Y; adj. EBITDA \$218M, up 1% Y/Y

Excluding FCS, Q3 2021 net sales up 19% Y/Y; adj. EBITDA up 14% Y/Y

Increased FY 2021 guidance based on strong Q3 performance

Announced acquisition agreement including a lithium conversion plant designed to produce up to 25,000 mtpa with the potential to expand to 50,000 mtpa

Announced agreements for strategic investments in China with plans to build two lithium hydroxide conversion plants, each initially targeting 50,000 mtpa

MARBL to restart operations at its Wodgina Lithium Mine; production expected to begin in Q3 2022

Well-Positioned to Drive Sustainable Growth

2021 OBJECTIVES **Updates** ✓ LAN III/IV construction complete Complete LAN III/IV (mid-2021) and KEM I/II (late 2021) Completion of KEM I YE '21; KEM II H2 '22 Grow Investment decisions on new expansion projects in Lithium and ✓ Announced new Li expansion projects **Profitably** Bromine ✓ New U.S. bromine brine well complete √ JBC tetrabrom debottleneck project complete Achieve \$75M productivity improvements versus 20201 Productivity objectives on track Preserve margins with best-in-class cost discipline and **Maximize** ✓ Launched Albemarle Way of Excellence continuous improvement **Productivity** (AWE), our focused operating model Build project execution expertise to accelerate highest return growth projects Align growth with commercial agreements to support economic ✓ FCS divestiture closed June 1, 2021 Catalysts strategic review underway returns Invest Continue to actively evaluate portfolio; complete FCS divestiture ✓ Investment Grade rating intact with Discipline Maintain Investment Grade credit rating and support our dividend √ 27th consecutive year of a dividend increase ✓ Initial sustainability targets set Set near-term sustainability targets; explore science-based target Advance ✓ Sustainability objectives on track options **Sustainability** ✓ First CDP report submitted Aug 2021 Partner with automotive OEMs to enable sustainable supply

✓ First lithium company to become IRMA

member

chains

Delivering Wave 2 Lithium Expansions in 2022


La Negra III / IV

- Conversion of low-cost, high-quality Chilean brine
- 40ktpa nameplate capacity lithium carbonate
- 100% owned and 100% marketed by ALB
- Achieved first production October 2021;
 progressing qualification process; first sales
 expected in H1 2022

Salar de Atacama La Negra

Kemerton I / II

- Conversion of low-cost, high-quality Australian spodumene
- 50ktpa nameplate capacity lithium hydroxide
- 60% owned and 100% marketed by ALB
- Prioritizing Kemerton I to mitigate risks related to labor shortages and pandemic-related travel restrictions in Western Australia
- Kemerton I: construction completion expected by YE 2021; first sales expected in H2 2022
- Kemerton II: construction completion now expected in H2 2022; first sales expected in 2023



Resource

Conversion



Progressing Wave 3 Conversion Capacity Expansions

Agreement to Acquire Guangxi Tianyuan New Energy Materials:

- Conversion plant designed to produce 25ktpa LCE (Qinzhou)
- Potential to expand to 50ktpa
- In commissioning; first sales expected H2 2022

Wodgina restart; expected to begin producing spodumene concentrate in Q3 2022

Investment agreements for two sites in China:


- Yangtze River Chemical Industrial Park (Zhangjiagang) and Sichuan Pengshan Economic Development Park (Meishan)
- Initial plan to build 50ktpa LiOH conversion plants at each site

Alignment with long-term strategy:

- Acquisition accelerates conversion capacity growth
- Expansion potential and improved optionality
- ✓ Increasing conversion capacity to leverage world-class resources
- Investments in low-cost jurisdictions reduce capital intensity and improve returns



Global Project Pipeline Offers Diversity, Scale & Optionality




















Q3 2021 Financial Summary


| (in millions, except per share amounts) | Q3 2021 | Q3 2020 | Variance |
|--|----------|---------|----------|
| Net Sales | \$831 | \$747 | 11% |
| Net income attributable to Albemarle Corporation | \$(393) | \$98 | -500% |
| Adjusted EBITDA | \$218 | \$216 | 1% |
| Adjusted EBITDA Margin | 26% | 29% | |
| Diluted EPS ¹ | \$(3.36) | \$0.92 | 465% |
| Non-operating pension and OPEB items | (0.04) | (0.02) | |
| Non-recurring and other unusual items ² | 4.42 | 0.19 | |
| Adjusted Diluted EPS ³ | \$1.05 | \$1.09 | -4% |



Q3 2021 Adjusted EBITDA Bridge



Financial Flexibility to Execute Growth Strategy



| Selected Financial Metrics | | | | | | | | | |
|----------------------------|-------------------|--|--|--|--|--|--|--|--|
| (\$ in millions) | (as of 9/30/2021) | | | | | | | | |
| Dividends Paid (TTM) | \$173 | | | | | | | | |
| Dividend Growth (TTM Y/Y) | 8.45% | | | | | | | | |
| Cash Balance | \$595 | | | | | | | | |
| Gross Debt ² | \$2,022 | | | | | | | | |
| | | | | | | | | | |

- Increased annual dividend for 27th consecutive year
- Intend to retain target long-term leverage ratio range of 2.0x 2.5x

Raising Full-Year 2021 Guidance

| | FY 2021 Guidance |
|--------------------------|---------------------|
| Net Sales | \$3.3B – \$3.4B |
| Adj. EBITDA | \$830M – \$860M 👚 |
| Adj. EBITDA Margin | ~25 % |
| Adj. Diluted EPS | \$3.85 – \$4.15 |
| Net Cash from Operations | \$550M - \$650M 👄 |
| Capital Expenditures | \$925M — \$975M 👚 |

All businesses contributed to improved 2021 Guidance:

- Lithium and Bromine: Stronger pricing due to tight market conditions
- Catalyst: Higher-than-expected joint venture income
- > Corporate: Lower costs

FY 2021: Improved Outlook Across our Businesses

As of November 4, 2021



- Lithium FY 2021 adj. EBITDA expected to be up mid- to high-teens Y/Y, up from previous guidance
- FY 2021 volume growth expected to be up mid-teens Y/Y due primarily to higher tolling volumes
- Average realized pricing expected to increase sequentially during the year, flat to slightly up on Y/Y basis
- Higher costs related to project start-ups and tolling, partially offset by productivity improvements



- Catalysts FY 2021 adj. EBITDA expected to be down 20% 25% Y/Y, an improvement from previous guidance owing to higher-than-expected equity income
- FY 2021 overall outlook primarily impacted by the U.S. Gulf Coast winter storm headwinds, product mix, and a change in customer order patterns during Q1
- Markets improving but volumes not expected to return to pre-pandemic levels before late '22 or '23



- Bromine FY 2021 adj. EBITDA expected to be up low double digits Y/Y, up from previous guidance
- Continued economic recovery and strength in flame retardants; benefiting from diverse end-markets
- Volumes constrained due to sold out conditions and lack of inventory
- Cost savings and higher pricing expected to partially offset higher freight and raw material costs



Clear Strategy to Accelerate Profitable Growth and Advance Sustainability



Enhancing strategy execution and long-term value creating with **focused**operating model — the Albemarle Way of Excellence (AWE)

Disciplined capital allocation priorities: accelerate profitable growth, maintain financial flexibility, and support shareholder returns

Significant growth expected by 2026: ~\$6-7B in revenue (>2x 2021); ~\$2-3B in adj. EBITDA (>3x 2021); ~\$2B in net cash from operations (>3x 2021)

Committed to industry-leading sustainability performance; partnering with our customers to make the world safer, more sustainable and environmentally sound


Lithium Overview

As of November 4, 2021

Q3 2021 PERFORMANCE

| (\$M) | Q3 2021 | ΔQ3 2020 |
|---------------------------|---------|----------|
| Net Sales | \$359 | 35% |
| Net Sales ex FX¹ | \$354 | 33% |
| Adj. EBITDA | \$125 | 28% |
| Adj. EBITDA ex FX¹ | \$123 | 26% |
| Adj. EBITDA Margin | 35% | -190 bps |
| Adj. EBITDA Margin ex FX¹ | 36% | -211 bps |

HISTORICAL TREND (TTM)



YoY Q3 Performance Drivers

- Net sales increased 35% (price³ +5%, volume +30%); adjusted EBITDA up 28%
- Adjusted EBITDA benefited from higher net sales and higher volumes at Talison JV
- Sales volumes increased primarily due to tolling production to help meet growing customer demand
- Further volume growth constrained by lack of inventory as customer orders were pulled forward into the first half of the year

FY 2021 Outlook

- FY 2021 adjusted EBITDA expected to be up mid- to high-teens Y/Y
- Volumes expected to increase mid-teens Y/Y driven primarily by tolling
- Average realized pricing expected to improve sequentially due to tightening market conditions, and full-year pricing will be flat to slightly up overall compared to 2020
- Higher costs related to project start-ups and tolling, partially offset by productivity improvements; FY 2021 average margin expected to remain below 35%

Drivers/Sensitivities

- Energy storage (~60% of Li sales²): Primary driver EV sales in Europe and China
 - Potential 1 to 2 quarter lag behind EV production
- Specialties and TG (~40% of Li sales²): Primary driver consumer spending and industrial production - less than 1 quarter lag


Catalysts Overview

As of November 4, 2021

Q3 2021 PERFORMANCE

| (\$M) | Q3 2021 | ΔQ3 2020 |
|---------------------------|---------|----------|
| Net Sales | \$194 | -2% |
| Net Sales ex FX¹ | \$193 | -3% |
| Adj. EBITDA | \$33 | -13% |
| Adj. EBITDA ex FX¹ | \$33 | -12% |
| Adj. EBITDA Margin | 17% | -201 bps |
| Adj. EBITDA Margin ex FX¹ | 17% | -183 bps |

HISTORICAL TREND (TTM)



YoY Q3 Performance Drivers

- Net sales down 2% (price³ -1%, volume -1%); adjusted EBITDA down 13%
- Adjusted EBITDA impacted by higher costs and lower sales, partially offset by higherthan-expected equity income
- Higher raw materials and freight costs continued to impact margins

FY 2021 Outlook

- FY 2021 adjusted EBITDA expected to decline by 20-25% Y/Y; improved from previous guidance due to higher-than-expected equity income
- Outlook impacted by winter storm headwinds, product mix, and a previously announced change in customer order patterns during Q1
- Market conditions improving, but volumes are not expected to return to pre-pandemic levels before late 2022 or 2023

Drivers/Sensitivities

- FCC (~ 50% of sales²): Primary drivers miles driven/transportation fuel consumption
- HPC (~ 30% of sales²): Primary drivers environmental sulfur regulations and miles driven/transportation fuel consumption
- PCS (~ 20% of sales²): Primary drivers plastic and polyurethane demand


Bromine Specialties Overview

As of November 4, 2021

Q3 2021 PERFORMANCE

| (\$M) | Q3 2021 | ΔQ3 2020 |
|---------------------------|---------|----------|
| Net Sales | \$278 | 17% |
| Net Sales ex FX¹ | \$276 | 16% |
| Adj. EBITDA | \$86 | 8% |
| Adj. EBITDA ex FX¹ | \$84 | 6% |
| Adj. EBITDA Margin | 31% | -253 bps |
| Adj. EBITDA Margin ex FX¹ | 31% | -296 bps |

HISTORICAL TREND (TTM)



YoY Q3 Performance Drivers

- Net sales up 17% (price³ +17%, volume +0%); adjusted EBITDA up 8%
- Favorable pricing driven by robust demand and tight market conditions
- Increase in net sales partially offset by higher costs for raw materials and freight
- Force majeure declaration by chlorine supplier limited ability to capitalize on demand strength and increased brine production capacity

FY 2021 Outlook

- Expect FY 2021 adjusted EBITDA up low double digits Y/Y, an improvement from previous guidance; chlorine supply is stabilizing but subject to availability
- Continued economic recovery and strength in flame retardants; benefitting from diverse end-markets
- Sold out conditions for the remainder of the year with no inventory
- On-going cost savings and higher pricing help offset higher freight and raw materials

Drivers/Sensitivities

- GDP plus business electronics, automotive, construction, appliances
- Flame retardants (~60% of sales²): Primary driver consumer spending, digitization, electrification
- Oilfield (<10% of sales²): Primary driver oil price
 - Deep water and off-shore drilling
- ~1 to 3 quarter lag in supply chain

Q4 2021 Investor Relations Events

| Date | Event – All Virtual |
|-------------|---|
| November 8 | Oppenheimer Fireside Chat |
| November 10 | Baird Global Industrial Conference |
| December 1 | Citi Basic Materials Virtual Conference |
| December 9 | Deutsche Bank Lithium and Battery Supply Chain Conference |

Meredith Bandy

VP, Investor Relations & Sustainability meredith.bandy@albemarle.com +1 980.999.5168

David Burke

Director, Investor Relations david.burke@albemarle.com +1 980.299.5533

Katie Pyfer

Manager, Investor Relations katheryne.pyfer@albemarle.com +1 980.299.5590



Appendix

Non-GAAP Reconciliations



Definitions of Non-GAAP Measures

| NON-GAAP MEASURE | DESCRIPTION |
|------------------------------------|---|
| Adjusted Net Income | Net income attributable to Albemarle Corporation before non-recurring, other unusual and non-operating pension and OPEB. |
| Pro-forma Adjusted Net Income | Net income attributable to Albemarle Corporation before non-recurring, other unusual and non-operating pension and OPEB items, and the net impact of the divested business. |
| Adjusted Diluted EPS | Diluted EPS before non-recurring, other unusual and non-operating pension and OPEB. |
| Pro-forma Adjusted Diluted EPS | Diluted EPS before non-recurring, other unusual and non-operating pension and OPEB items, and the net impact of the divested business. |
| EBITDA | Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, and depreciation and amortization. |
| Adjusted EBITDA | EBITDA before non-recurring, other unusual and non-operating pension and OPEB. |
| Pro-forma Adjusted EBITDA | Adjusted EBITDA before the net impact of EBITDA of the divested business. |
| Pro-forma Net Sales | Net Sales before the impact of Net Sales from the divested business. |
| Adjusted Effective Income Tax Rate | Reported effective income tax rate before the tax impact of non-recurring, other unusual and non-operating pension and OPEB items. |



Adjusted Net Income

| | Three Mon Septem | | | | | |
|---|---------------------|-----|---------|--|--|--|
| (\$ in thousands) | 2021 | DCI | 2020 | | | |
| Net (loss) income attributable to Albemarle Corporation | \$ (392,781) | \$ | 98,301 | | | |
| Add back: | | | | | | |
| Non-operating pension and OPEB items (net of tax) | (4,271) | | (2,294) | | | |
| Non-recurring and other unusual items (net of tax) | 520,392 | | 20,278 | | | |
| Adjusted net income attributable to Albemarle Corporation | \$ 123,340 | \$ | 116,285 | | | |
| | | | | | | |
| Adjusted diluted earnings per share | \$ 1.05 | \$ | 1.09 | | | |
| | | | | | | |
| Weighted-average common shares outstanding – diluted | 117,685 | | 106,873 | | | |

See above for a reconciliation of adjusted net income, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP.



EBITDA and Adjusted EBITDA

| | | Months Ended otember 30, | | | | |
|--|-----------------|-----------------------------|----------|--|--|--|
| (\$ in thousands) | 2021 | | 2020 | | | |
| Net (loss) income attributable to Albemarle Corporation | \$ (392,781) | \$ | 98,301 | | | |
| Add back: | | | | | | |
| Interest and financing expenses | 5,136 | | 19,227 | | | |
| Income tax expense | (114,670) | | 30,653 | | | |
| Depreciation and amortization | 62,082 | | 58,679 | | | |
| EBITDA | (440,233) | | 206,860 | | | |
| Non-operating pension and OPEB items | (5,471) | | (2,901) | | | |
| Non-recurring and other unusual items | 663,273 | | 12,096 | | | |
| Adjusted EBITDA | \$ 217,569 | \$ | 216,055 | | | |
| Net impact of adjusted EBITDA from divested business | _ | | (21,791) | | | |
| Adjusted EBITDA excluding impact from divested business | \$ 217,569 | \$ | 194,264 | | | |
| Net sales | \$ 830,566 | \$ | 746,868 | | | |
| Net impact of net sales from divested business | _ | | (42,195) | | | |
| Net sales excluding impact from divested business | \$ 830,566 | \$ | 704,673 | | | |
| EBITDA margin | (53.0)% | | 27.7 % | | | |
| Adjusted EBITDA margin | 26.2 % | | 28.9 % | | | |
| Adjusted EBITDA margin excluding impact from divested businesses | 26.2 % | | 27.6 % | | | |

See above for a reconciliation of EBITDA, adjusted EBITDA and the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP.



Adjusted EBITDA – by Segment (three months ended)

| (\$ in thousands) | Lithium | | Bromine Specialties Catalysts | | Catalysts | Reportable Segments Total | | | All Other | Corporate | | | Consolidated Total | |
|---|------------|----|----------------------------------|----|-----------|------------------------------|---------|----|-----------|-----------|-----------|----|-----------------------|--|
| Three months ended September 30, 2021 | | | | | | | | | | Т | | | | |
| Net income (loss) attributable to Albemarle Corporation | \$ 92,449 | \$ | 73,409 | \$ | 20,039 | \$ | 185,897 | \$ | _ | \$ | (578,678) | \$ | (392,781) | |
| Depreciation and amortization | 34,256 | | 12,603 | | 13,064 | | 59,923 | | _ | | 2,159 | | 62,082 | |
| Non-recurring and other unusual items | (1,289) |) | _ | | _ | | (1,289) | | _ | | 664,562 | | 663,273 | |
| Interest and financing expenses | _ | | _ | | _ | | _ | | _ | | 5,136 | | 5,136 | |
| Income tax expense | _ | | _ | | _ | | _ | | _ | | (114,670) | | (114,670) | |
| Non-operating pension and OPEB items | _ | | _ | | _ | | | | _ | | (5,471) | | (5,471) | |
| Adjusted EBITDA | \$ 125,416 | \$ | 86,012 | \$ | 33,103 | \$ | 244,531 | \$ | _ | \$ | (26,962) | \$ | 217,569 | |
| | | | | | | | | | | | | | | |
| Three months ended September 30, 2020 | | | | | | | | | | | | | | |
| Net income (loss) attributable to Albemarle Corporation | \$ 69,102 | \$ | 66,548 | \$ | 25,176 | \$ | 160,826 | \$ | 22,798 | \$ | (85,323) | \$ | 98,301 | |
| Depreciation and amortization | 28,687 | | 12,900 | | 12,658 | | 54,245 | | 2,187 | | 2,247 | | 58,679 | |
| Non-recurring and other unusual items | _ | | _ | | _ | | _ | | _ | | 12,096 | | 12,096 | |
| Interest and financing expenses | _ | | _ | | _ | | _ | | _ | | 19,227 | | 19,227 | |
| Income tax expense | _ | | _ | | _ | | _ | | _ | | 30,653 | | 30,653 | |
| Non-operating pension and OPEB items | _ | | _ | | _ | | _ | | _ | | (2,901) | | (2,901) | |
| Adjusted EBITDA | \$ 97,789 | \$ | 79,448 | \$ | 37,834 | \$ | 215,071 | \$ | 24,985 | \$ | (24,001) | \$ | 216,055 | |
| Net impact of adjusted EBITDA from divested business | _ | | _ | | _ | | _ | | (21,791) | | _ | | (21,791) | |
| Adjusted EBITDA excluding impact from divested business | \$ 97,789 | \$ | 79,448 | \$ | 37,834 | \$ | 215,071 | \$ | 3,194 | \$ | (24,001) | \$ | 194,264 | |



Adjusted EBITDA – Margin by Segment (three months ended)

| (\$ in thousands) | | Lithium | Bromine um Specialties | | Catalysts | | | Reportable Segments Total | All Other | | Cor | solidated Total |
|--|----|----------|---------------------------|----------|-----------|----------|----|------------------------------|-----------|----------|-----|-----------------|
| Three months ended September 30, 2021 | | | | | | | | | | | | |
| Net sales | \$ | 359,229 | \$ | 277,783 | \$ | 193,554 | \$ | 830,566 | | | \$ | 830,566 |
| Pro-forma: Net impact of net sales from divested business | , | _ | | _ | | _ | | _ | | | | _ |
| Pro-forma net sales | \$ | 359,229 | \$ | 277,783 | \$ | 193,554 | \$ | 830,566 | | | \$ | 830,566 |
| Net income (loss) attributable to Albemarle Corporation | | 25.7 % | | 26.4 % | | 10.4 % | | 22.4 % | | | | (47.3)% |
| Depreciation and amortization | | 9.5 % | | 4.5 % | | 6.7 % | | 7.2 % | | | | 7.5 % |
| Non-recurring and other unusual items | | (0.4)% | | — % | | — % | | (0.2)% | | | | 79.9 % |
| Interest and financing expenses | | — % | | — % | | — % | | — % | | | | 0.6 % |
| Income tax expense | | — % | | — % | | — % | | — % | | | | (13.8)% |
| Non-operating pension and OPEB items | | — % | | — % | | — % | | — % | | | | (0.7)% |
| Adjusted EBITDA Margin | | 34.9 % | | 31.0 % | | 17.1 % | | 29.4 % | | | | 26.2 % |
| | | | | | | | | | | | | |
| Three months ended September 30, 2020 | | | | | | | | | | | | |
| Net sales | \$ | 265,646 | \$ | 237,193 | \$ | 197,919 | \$ | 700,758 | \$ | 46,110 | \$ | 746,868 |
| Net impact of net sales from divested business | | | | | | | | | | (42,195) | | (42,195) |
| Net sales excluding impact from divested business | \$ | 265,646 | \$ | 237,193 | \$ | 197,919 | \$ | 700,758 | \$ | 3,915 | \$ | 704,673 |
| Net income (loss) attributable to Albemarle Corporation | | 26.0 % | | 28.1 % | | 12.7 % | | 23.0 % | | 49.4 % | | 13.2 % |
| Depreciation and amortization | | 10.8 % | | 5.4 % | | 6.4 % | | 7.7 % | | 4.7 % | | 7.9 % |
| Non-recurring and other unusual items | | — % | | — % | | — % | | — % | | — % | | 1.6 % |
| Interest and financing expenses | | — % | | — % | | — % | | — % | | — % | | 2.6 % |
| Income tax expense | | — % | | — % | | — % | | — % | | — % | | 4.1 % |
| Non-operating pension and OPEB items | | <u> </u> | | <u> </u> | | <u> </u> | _ | <u> </u> | | <u> </u> | | (0.4)% |
| Adjusted EBITDA Margin | | 36.8 % | | 33.5 % | | 19.1 % | | 30.7 % | | 54.2 % | | 28.9 % |
| | | | | | | | | | | | | |
| Adjusted EBITDA margin excluding impact from divested businesses | | 36.8 % | | 33.5 % | | 19.1 % | | 30.7 % | | 81.6 % | | 27.6 % |

See above for adjusted EBITDA margin, a non-GAAP financial measure defined as adjusted EBITDA divided by net sales. See previous slide for the related reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP.



Adjusted EBITDA – by Segment (twelve months ended)

| | | Twelve Months Ended | | | | | | | | | | | | |
|--|----|---------------------|----|--------------|----------|--------------|------|--------------|------|--------------|--|--|--|--|
| (\$ in thousands) | | Sep 30, 2020 | | Dec 31, 2020 | N | Mar 31, 2021 | | Jun 30, 2021 | | Sep 30, 2021 | | | | |
| Lithium | | | | | | | | | | | | | | |
| Net income attributable to Albemarle Corporation | \$ | 217,538 | \$ | 277,711 | \$ | 294,843 | \$ | 303,398 | \$ | 326,745 | | | | |
| Depreciation and amortization | | 110,337 | | 112,854 | | 119,263 | | 124,262 | | 129,831 | | | | |
| Non-recurring and other unusual items | | 83,167 | | 2,528 | | 6,786 | | 8,137 | | 6,848 | | | | |
| Adjusted EBITDA | | 411,042 | | 393,093 | | 420,892 | | 435,797 | | 463,424 | | | | |
| Net Sales | | 1,197,326 | | 1,144,778 | | 1,186,936 | | 1,223,548 | | 1,317,131 | | | | |
| Adjusted EBITDA Margin | | 34 % 34 | | 34 % | . | 35 % | 36 % | | | 35 % | | | | |
| Bromine Specialties | | | | | | | | | | | | | | |
| Net income attributable to Albemarle Corporation | \$ | 266,530 | \$ | 274,495 | \$ | 284,943 | \$ | 304,399 | \$ | 311,260 | | | | |
| Depreciation and amortization | | 49,176 | | 50,310 | | 51,240 | | 51,389 | | 51,092 | | | | |
| Non-recurring and other unusual items | | (241) | | (1,200) | | (1,200) | | (1,200) | | (1,200) | | | | |
| Adjusted EBITDA | | 315,465 | | 323,605 | | 334,983 | | 354,588 | | 361,152 | | | | |
| Net Sales | | 945,028 | | 964,962 | | 1,013,817 | | 1,060,786 | | 1,101,376 | | | | |
| Adjusted EBITDA Margin | | 33 % | | 34 % | % 33 % | | | 33 % | 33 % | | | | | |
| Catalysts | | | | | | | | | | | | | | |
| Net income attributable to Albemarle Corporation | \$ | 134,128 | \$ | 80,149 | \$ | 58,173 | \$ | 55,917 | \$ | 50,780 | | | | |
| Depreciation and amortization | | 49,893 | | 49,985 | | 49,918 | | 50,561 | | 50,967 | | | | |
| Non-recurring and other unusual items | | 794 | | _ | | _ | | _ | | _ | | | | |
| Adjusted EBITDA | | 184,815 | | 130,134 | | 108,091 | | 106,478 | | 101,747 | | | | |
| Net Sales | | 884,701 | | 797,914 | | 810,950 | | 762,241 | | 757,876 | | | | |
| Adjusted EBITDA Margin | | 21 % | | 16 % | 5 | 13 % | 14 % | | | 13 % | | | | |



Adjusted EBITDA supplemental¹

| (\$ in thousands) | Twe | lve Months Ended | | Three Months Ended | | | | | | | | |
|---|-----|---------------------|----|--------------------|----|--------------|-----------------|----------|----|--------------|--|--|
| | Se | p 30, 2021 | Se | ep 30, 2021 | J | lun 30, 2021 | 21 Mar 31, 2021 | | | Dec 31, 2020 | | |
| Adjusted EBITDA | \$ | 863,376 | \$ | 217,569 | \$ | 194,628 | \$ | 230,054 | \$ | 221,125 | | |
| Adjusted EBITDA of divested businesses | | (44,866) | | _ | | (6,990) | | (21,425) | | (16,451) | | |
| Net income attributable to noncontrolling interests | | 79,519 | | 18,348 | | 21,608 | | 22,021 | | 17,542 | | |
| Equity in net income of unconsolidated investments (net of tax) | | (105,864) | | (27,706) | | (17,998) | | (16,511) | | (43,649) | | |
| Dividends received from unconsolidated investments | | 70,226 | | 15,954 | | 22,470 | | 4,950 | | 26,852 | | |
| Consolidated EBITDA | \$ | 862,391 | \$ | 224,165 | \$ | 213,718 | \$ | 219,089 | \$ | 205,419 | | |
| | | | | | | | | | | | | |
| Total Long Term Debt (as reported) | \$ | 2,022,098 | | | | | | | | | | |
| Off balance sheet obligations and other | | 81,800 | | | | | | | | | | |
| Consolidated Funded Debt | \$ | 2,103,898 | | | | | | | | | | |
| Less Cash | | 595,049 | | | | | | | | | | |
| Consolidated Funded Net Debt | \$ | 1,508,849 | | | | | | | | | | |
| | | | | | | | | | | | | |
| Consolidated Funded Debt to Consolidated EBITDA Ratio | | 2.4 | | | | | | | | | | |
| Consolidated Funded Net Debt to Consolidated EBITDA Ratio | | 1.7 | | | | | | | | | | |

Diluted EPS

Three Months Ended September 30, 2021 2020 \$ (3.36) \$ Diluted earnings per share attributable to Albemarle Corporation 0.92 Add back: Non-operating pension and OPEB items (net of tax) (0.04)(0.02)Non-recurring and other unusual items (net of tax) Restructuring and other 0.02 0.01 Acquisition and integration related costs 0.04 Gain on sale of business 0.01 4.29 Legal accrual Other 0.02 0.02 Discrete tax items 0.09 0.11 4.42 Total non-recurring and other unusual items 0.19 Adjusted diluted earnings per share¹ 1.05 \$ 1.09 Diluted Shares 116,965 106.873



¹Totals may not add due to rounding

Effective Tax Rate

| (\$ in thousands) | ` incó equity of ur | income before me taxes and in net income aconsolidated evestments | tax (benefit) kpense | Effective income tax rate |
|---|---------------------------|---|-------------------------|---------------------------|
| Three months ended September 30, 2021 | | | | |
| As reported | \$ | (516,809) | \$ (114,670) | 22.2 % |
| Non-recurring, other unusual and non-operating pension and OPEB items | | 657,802 | 141,681 | |
| As adjusted | \$ | 140,993 | \$ 27,011 | 19.2 % |
| | | | | |
| Three months ended September 30, 2020 | | | | |
| As reported | \$ | 121,544 | \$ 30,653 | 25.2 % |
| Non-recurring, other unusual and non-operating pension and OPEB items | | 9,195 | (8,789) | |
| As adjusted | \$ | 130,739 | \$ 21,864 | 16.7 % |
| | | | | |

See above for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reporting in accordance with GAAP.



Equity Income and Noncontrolling Interest

| | Three Months Ended September 30, | | | | | | | | | | |
|---------------------|----------------------------------|---------------|----|----------------------------|----|---------------|----|----------------------------|--|--|--|
| | 2021 | | | | | 2020 | | | | | |
| (\$ in thousands) | | Equity Income | | Noncontrolling Interest | | Equity Income | | Noncontrolling Interest | | | |
| Lithium | \$ | 21,664 | \$ | , — | \$ | 19,756 | \$ | _ | | | |
| Bromine Specialties | | _ | | (18,354) | | _ | | (18,750) | | | |
| Catalysts | | 10,768 | | _ | | 705 | | _ | | | |
| Corporate | | (4,726) | | 6 | | 5,693 | | 6 | | | |
| Total Company | \$ | 27,706 | \$ | (18,348) | \$ | 26,154 | \$ | (18,744) | | | |



www.albemarle.com